+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
Healthy Volunteers
ID07214324

Study Using Multiple Biological Analyses to Understand and Predict Progression of Monoclonal Gammopathies Including MGUS, SMM, and Multiple Myeloma

Led by Azienda USL Reggio Emilia - IRCCS · Updated on 2026-04-23

60

Participants Needed

4

Research Sites

72 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying monoclonal gammopathy of undetermined significance MGUS, smoldering multiple myeloma SMM, and multiple myeloma MM to identify molecular and immune markers linked to disease progression. This observational study integrates genomic, transcriptomic, immunophenotypic, and oral microbiome analyses to better understand how these conditions evolve into symptomatic MM. The study also includes in vitro experiments to explore bone damage and immune system dysfunction, aiming to improve early risk assessment and support future preventive treatments. Participants include patients with MGUS, SMM, or MM, as well as healthy volunteers undergoing joint replacement surgery for osteoarthritis who serve as controls. Biological samples such as bone marrow aspirates, biopsies, peripheral blood, and gingival crevicular fluid are collected during routine care or surgery. The study follows patients up to 24 months, analyzing their immune cells, genetic profiles, and oral microbiome to unravel disease mechanisms and progression markers. Participants will undergo several assessments including immunophenotypic characterization of bone marrow and blood, genomic and transcriptomic profiling of plasma cells, and single-cell and spatial transcriptomic analyses. Oral microbiome composition will also be evaluated. Researchers will validate genetic profiles related to bone disease using functional studies. The study involves routine collection of leftover clinical samples and non-invasive fluid samples, with all procedures designed to understand disease biology and improve future risk prediction over a two-year period.

CONDITIONS

Brief Title

Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution

Research Team

N

Noemi Puccio

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here